UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 188

Sortiert nach

Bone Marrow: The Central Immune System

Immuno, 2023-09, Vol.3 (3), p.289-329

Schirrmacher, Volker

2023

Volltextzugriff (PDF)

Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer

Methods in molecular biology (Clifton, N.J.), 2009, Vol.542, p.565

2009

Volltextzugriff (PDF)

Activation of Natural Killer Cells by Newcastle Disease Virus Hemagglutinin-Neuraminidase

Journal of Virology, 2009-08, Vol.83 (16), p.8108-8121

2009

Volltextzugriff (PDF)

Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance

Expert opinion on biological therapy, 2015-12, Vol.15 (12), p.1757-1771

Schirrmacher, Volker

2015

Volltextzugriff (PDF)

Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function

Expert review of vaccines, 2014-01, Vol.13 (1), p.117-130

2014

Volltextzugriff (PDF)

Cell Surface Expression and Secretion of Heparanase Markedly Promote Tumor Angiogenesis and Metastasis

Proceedings of the National Academy of Sciences - PNAS, 2002-07, Vol.99 (15), p.10031-10036

2002

Volltextzugriff (PDF)

Harnessing oncolytic virus-mediated immunity

2015

Volltextzugriff (PDF)

Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons from GvL studies in animals

Cancer Immunology, Immunotherapy, 2014-06, Vol.63 (6), p.535-543

Schirrmacher, Volker

2014

Volltextzugriff (PDF)

Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer: Preparing for the Future

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2013-02, Vol.27 (1), p.35-53

2013

Volltextzugriff (PDF)

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

Cancer Immunology, Immunotherapy, 2005-06, Vol.54 (6), p.587-598

Schirrmacher, Volker

2005

Volltextzugriff (PDF)

IMMU-25. SYNERGY BETWEEN TMZ AND INDIVIDUALIZED MULTIMODAL IMMUNOTHERAPY TO IMPROVE OS OF IDH1 WILD TYPE MGMT PROMOTOR UNMETHYLATED GBM PATIENTS

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi97-vi97

2021

Volltextzugriff (PDF)

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

Genes and immunity, 2022-12, Vol.23 (8), p.255-259

2022

Volltextzugriff (PDF)

IMMU-02. CMV-EXPANDED T-CELLS IN GLIOBLASTOMA PATIENTS: TRANSLATIONAL RESEARCH

Neuro-oncology (Charlottesville, Va.), 2023-06, Vol.25 (Supplement_1), p.i49-i49

2023

Volltextzugriff (PDF)

Influence of Adjuvant Hormone Therapy and Chemotherapy on the Immune System Analysed in the Bone Marrow of Patients with Breast Cancer

Clinical cancer research, 2003-01, Vol.9 (1), p.174-180

2003

Volltextzugriff (PDF)

INNV-18. MULTIPHASE COMBINED TREATMENT, INCLUDING INDIVIDUALIZED MULTIMODAL IMMUNOTHERAPY FOR ADULTS WITH GBM: SINGLE INSTITUTE REAL WORLD MEDICAL DATA IN THE LIGHT OF CLINICAL TRIAL RESEARCH DATA

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v160-v160

2023

Volltextzugriff (PDF)

QOL-02. MONITORING GBM PATIENT HEALTH-RELATED QUALITY OF LIFE AND QUALITY ADJUSTED LIFE MONTHS DURING INDIVIDUALIZED MULTIMODAL IMMUNOTHERAPY USING EQ-5D-5L

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v248-v248

2023

Volltextzugriff (PDF)

IMMU-03. Synergy between TMZ and individualized multimodal immunotherapy to improve Overall Survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i81-i81

2022

Volltextzugriff (PDF)

IMMU-07. IMMUNOGENIC CELL DEATH DURING MAINTENANCE CHEMOTHERAPY AND SUBSEQUENT MULTIMODAL IMMUNOTHERAPY FOR GBM

Neuro-oncology (Charlottesville, Va.), 2018-06, Vol.20 (suppl_2), p.i99-i100

2018

Volltextzugriff (PDF)

Randomized clinical studies of anti-tumor vaccination: state of the art in 2008

Expert review of vaccines, 2009-01, Vol.8 (1), p.51-66

2009

Volltextzugriff (PDF)

Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus

Cancer gene therapy, 2005-03, Vol.12 (3), p.295-303

2005

Volltextzugriff (PDF)

PDCT-15. MULTIMODAL IMMUNOTHERAPY AS PART OF MULTIMODAL TREATMENT FOR DIPG

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi187-vi187

2017

Volltextzugriff (PDF)

DIPG-38. ADDITION OF MULTIMODAL IMMUNOTHERAPY TO COMBINATION TREATMENT STRATEGIES FOR CHILDREN WITH DIPG: FINAL RESULTS OF A COHORT OF CHILDREN

Neuro-oncology (Charlottesville, Va.), 2020-12, Vol.22 (Supplement_3), p.iii294-iii294

2020

Volltextzugriff (PDF)

Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies

Expert review of anticancer therapy, 2020-08, Vol.20 (8), p.639-646

2020

Volltextzugriff (PDF)

DIPG-10. MULTIMODAL IMMUNOTHERAPY AS PART OF MULTIMODAL TREATMENT FOR DIPG

Neuro-oncology (Charlottesville, Va.), 2017-06, Vol.19 (suppl_4), p.iv6-iv7

2017

Volltextzugriff (PDF)

Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients

Methods in cell biology, 2024, Vol.183, p.51-113

2024

Volltextzugriff (PDF)

1 – 25 von 188

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

ThemaMice, Inbred Dba

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(168)
Mit Volltextzugriff
(169)

Publikationsform

Sprache

Englisch
(179)
Japanisch
(10)
Deutsch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(106)
Life Sciences & Biomedicine
(101)
Humans
(78)
Animals
(70)
Oncology
(60)
Biological And Medical Sciences
(49)
Mice
(49)
Medical Sciences
(42)
Female
(34)
Tumors
(32)
T-Lymphocytes - Immunology
(30)
Immunology
(29)
Newcastle Disease Virus
(24)
Immunotherapy
(23)
Newcastle Disease Virus - Immunology
(18)
Pharmacology. Drug Treatments
(16)
Antineoplastic Agents
(15)
Medicine, Research & Experimental
(15)
Research & Experimental Medicine
(15)
Tumor Cells, Cultured
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bone Marrow: The Central Immune System

Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer

Activation of Natural Killer Cells by Newcastle Disease Virus Hemagglutinin-Neuraminidase

Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance

Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function

Cell Surface Expression and Secretion of Heparanase Markedly Promote Tumor Angiogenesis and Metastasis

Harnessing oncolytic virus-mediated immunity

Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons from GvL studies in animals

Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer: Preparing for the Future

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

IMMU-25. SYNERGY BETWEEN TMZ AND INDIVIDUALIZED MULTIMODAL IMMUNOTHERAPY TO IMPROVE OS OF IDH1 WILD TYPE MGMT PROMOTOR UNMETHYLATED GBM PATIENTS

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

IMMU-02. CMV-EXPANDED T-CELLS IN GLIOBLASTOMA PATIENTS: TRANSLATIONAL RESEARCH

Influence of Adjuvant Hormone Therapy and Chemotherapy on the Immune System Analysed in the Bone Marrow of Patients with Breast Cancer

INNV-18. MULTIPHASE COMBINED TREATMENT, INCLUDING INDIVIDUALIZED MULTIMODAL IMMUNOTHERAPY FOR ADULTS WITH GBM: SINGLE INSTITUTE REAL WORLD MEDICAL DATA IN THE LIGHT OF CLINICAL TRIAL RESEARCH DATA

QOL-02. MONITORING GBM PATIENT HEALTH-RELATED QUALITY OF LIFE AND QUALITY ADJUSTED LIFE MONTHS DURING INDIVIDUALIZED MULTIMODAL IMMUNOTHERAPY USING EQ-5D-5L

IMMU-03. Synergy between TMZ and individualized multimodal immunotherapy to improve Overall Survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

IMMU-07. IMMUNOGENIC CELL DEATH DURING MAINTENANCE CHEMOTHERAPY AND SUBSEQUENT MULTIMODAL IMMUNOTHERAPY FOR GBM

Randomized clinical studies of anti-tumor vaccination: state of the art in 2008

Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus

PDCT-15. MULTIMODAL IMMUNOTHERAPY AS PART OF MULTIMODAL TREATMENT FOR DIPG

DIPG-38. ADDITION OF MULTIMODAL IMMUNOTHERAPY TO COMBINATION TREATMENT STRATEGIES FOR CHILDREN WITH DIPG: FINAL RESULTS OF A COHORT OF CHILDREN

Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies

DIPG-10. MULTIMODAL IMMUNOTHERAPY AS PART OF MULTIMODAL TREATMENT FOR DIPG

Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients

Aktive Filter

Suchergebnisse filtern